Drugs in MeSH Category Hallucinogens

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	201463-003	May 18, 2018		DISCN	No	No
Benuvia Operations	SYNDROS	dronabinol	SOLUTION;ORAL	205525-001	Mar 23, 2017		DISCN	Yes	No			Y	Y
Insys Therap	DRONABINOL	dronabinol	CAPSULE;ORAL	078501-001	Aug 19, 2011		DISCN	No	No
Benuvia Operations	SYNDROS	dronabinol	SOLUTION;ORAL	205525-001	Mar 23, 2017		DISCN	Yes	No			Y	Y
Insys Therap	DRONABINOL	dronabinol	CAPSULE;ORAL	078501-003	Aug 19, 2011		DISCN	No	No

Hallucinogens Market Analysis and Financial Projection

The global market for hallucinogenic drugs is undergoing rapid transformation, driven by shifting regulatory landscapes, breakthrough clinical research, and contentious intellectual property battles. Valued at $1.6 billion in 2022, the market is projected to grow at 12.1–13.4% annually through 2032, potentially reaching $7.8 billion[1][17]. This growth intersects with a surge in patent filings—over 330 psilocybin-related patents alone—as pharmaceutical companies race to commercialize therapies for mental health disorders[7][18].

---

Market Dynamics

Growth Drivers

• Mental health crisis: Depression affects 280 million globally, while PTSD impacts 6% of U.S. adults, accelerating demand for psychedelic therapies[1][6].
• Regulatory shifts: FDA designations (e.g., COMPASS Pathways' psilocybin for treatment-resistant depression) and decriminalization in Oregon/Colorado have enabled clinical trials and commercialization[11][18].
• Therapeutic innovation: Intranasal ketamine (Spravato) and oral psilocybin formulations dominate clinical pipelines, with phase III trials showing 60–70% remission rates for depression[11][16].

Regional Insights	Region	Market Share (2024)	Key Factors
North America	56%	FDA approvals, $318M in venture funding for psychedelic startups[11]
Europe	24%	Germany leads with 18 active clinical trials on MDMA-assisted therapy[11]
Asia-Pacific	12%	Rising R&D investments in Australia’s psilocybin depression trials[11]

Hospital pharmacies account for 56% of distribution due to strict prescription requirements for Schedule I substances like ketamine and LSD[16].

---

Patent Landscape Challenges

Key Trends

1. Monopoly strategies: Companies use "evergreening" tactics to extend patent lifetimes. Example: Roche/Genentech’s 48-year Herceptin monopoly model being adapted for psychedelics[2].
2. Biopiracy risks: 68% of psilocybin patents derive from Indigenous knowledge of mushroom cultivation, raising ethical concerns about compensation[4][15].
3. Prior art battles: Nonprofits like Freedom to Operate challenge patents (e.g., COMPASS’ crystalline psilocybin formulations) using historical ethnobotanical records[7][12].

Notable Cases

• COMPASS Pathways: Holds 9 psilocybin patents, including extraction methods (US Patent 10,954,259) and PTSD protocols. Two patents survived PTAB challenges in 2023[12][18].
• Silo Wellness: Developed psilocybin nasal spray despite unresolved patent conflicts over delivery mechanisms[11].

Mitigation Strategies

• Prior art repositories: Porta Sophia’s database documents 170 psychedelic use cases pre-dating 1960 to invalidate weak patents[15].
• Patent pledges: 23 companies have pledged open licensing for non-commercial research since 2022[4].

---

Regulatory and Ethical Crossroads

Legal frameworks struggle to balance innovation with equity:

• FDA designations: 14 psychedelics now have Breakthrough Therapy status, expediting trials but favoring corporate IP over public-domain research[13][18].
• UN drug policy: Psilocybin remains Schedule I under international treaties, complicating export/import for global trials[18].

Critics argue current patent practices could inflate treatment costs to $15,000 per dose for psilocybin therapy—10× the price of conventional antidepressants[15][18].

---

The hallucinogen market’s trajectory hinges on resolving tensions between pharmaceutical commercialization and psychedelics’ roots in communal healing. While patents drive investment, they risk stifling access to therapies that Indigenous cultures have stewarded for millennia. Regulatory reforms and ethical IP practices will determine whether this paradigm shift in mental healthcare achieves equitable impact.

References

1. https://www.alliedmarketresearch.com/psychedelic-drugs-market-A12068
2. https://hopp.uwpress.org/content/65/1/117
3. https://en.wikipedia.org/wiki/Hallucinogen
4. https://ir.law.fsu.edu/articles/736/
5. https://en.wikipedia.org/wiki/Antipsychotic
6. https://www.thebusinessresearchcompany.com/report/psychedelic-drugs-global-market-report
7. https://psychedelics.berkeley.edu/patents/
8. https://journals.sagepub.com/doi/10.1177/02698811231211219
9. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2017.00240/full
10. https://pharsight.greyb.com/collections/drugs-opening-to-patent-challenges-in-2025
11. https://www.stellarmr.com/report/Psychedelic-Drugs-Market/296
12. https://www.finnegan.com/en/insights/articles/patenting-treatments-involving-schedule-i-substances.html
13. https://pubmed.ncbi.nlm.nih.gov/29162429/
14. https://meshb-prev.nlm.nih.gov/record/ui?name=Hallucinogens
15. https://pubmed.ncbi.nlm.nih.gov/37796629/
16. https://www.mordorintelligence.com/industry-reports/psychedelic-drugs-market
17. https://www.grandviewresearch.com/industry-analysis/psychedelic-drugs-market-report
18. https://www.psilocybinsf.com/blog/navigating-the-psilocybin-legal-and-patent-landscape